Sanofi has stopped the phase 3 MOBILIZE clinical trial of riliprubart for treating chronic inflammatory demyelinating polyneuropathy (CIDP) after an interim review showed the study is unlikely to demonstrate sufficient efficacy. No safety concerns were found with riliprubart. Sanofi will analyze the data further and decide on continuing other riliprubart studies, including the VITALIZE trial. The termination will not impact Sanofi's 2026 financial guidance and involves no significant cost.
HR Tech 2026, scheduled for October 20-22 in Las Vegas, announced its agenda centered on real-world AI implementation, workforce skills, and HR transformation. The event features sessions from leaders at major companies like IFF, Lumen, and Sanofi, c...
Kymera Therapeutics has dosed the first participant in the Phase 1 clinical trial of KT-485, an oral IRAK4 degrader, marking a key milestone under its collaboration with Sanofi. This event triggered a $20 million milestone payment from Sanofi to Kyme...
